Asia-Pacific electronic drug delivery systems market is projected to register a substantial CAGR of 10.2% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
Asia-Pacific Electronic Drug Delivery Systems Market, By Type (Electronic Infusion Pumps, Electronic Injection Pens, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others), Country (Japan, China, South Korea, Australia, India, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the Asia-Pacific electronic drug delivery systems market are:

• Increase in geriatric patient pool susceptible to cardiovascular and respiratory disorders
• High prevalence of various chronic disorders

Market Players:
The key market players for Asia-Pacific electronic drug delivery systems market are listed below:

• AstraZeneca
• Amgen Inc.
• Ypsomed AG
• Merck KGaA
• Bayer AG
• F. Hoffmann-La Roche Ltd
• AptarGroup, Inc.
• Novo Nordisk A/S.
• Medtronic
• United Therapeutics Corporation
• BD
• B. Braun Melsungen AG
• West Pharmaceutical Services, Inc.